Sisram Medical Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sisram Medical de 11.5% y 8.4%, respectivamente.

Información clave

11.5%

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	34.5%
Tasa de crecimiento de los ingresos	8.4%
Rentabilidad financiera futura	8.3%
Cobertura de analistas	Low
Última actualización	31 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

May 30

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Apr 19

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Mar 01

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Jan 12

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Dec 21

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Dec 01

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Oct 14

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Sep 28

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Aug 25

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Aug 01

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

May 19

Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?

May 03

If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late

Apr 11

Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital

Mar 17

Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?

Nov 22

Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Aug 22

Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital

Jul 27

Here's Why We Think Sisram Medical Ltd's (HKG:1696) CEO Compensation Looks Fair

Jun 24

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Apr 16

Sisram Medical (HKG:1696) Has A Pretty Healthy Balance Sheet

Mar 26

Is Sisram Medical Ltd (HKG:1696) At Risk Of Cutting Its Dividend?

Mar 05

Sisram Medical (HKG:1696) Shareholders Booked A 79% Gain In The Last Year

Feb 12

Previsiones de crecimiento de beneficios e ingresos

SEHK:1696 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	456	44	N/A	42	1
12/31/2025	438	41	N/A	27	2
12/31/2024	395	35	N/A	25	2
12/31/2023	359	31	35	44	N/A
9/30/2023	355	35	-5	32	N/A
6/30/2023	352	38	-46	19	N/A
3/31/2023	353	39	-44	21	N/A
12/31/2022	354	40	-42	22	N/A
9/30/2022	349	38	-11	22	N/A
6/30/2022	344	35	19	22	N/A
3/31/2022	319	33	24	27	N/A
12/31/2021	294	31	29	32	N/A
9/30/2021	255	28	35	40	N/A
6/30/2021	216	24	42	47	N/A
3/31/2021	189	19	29	36	N/A
12/31/2020	162	13	16	26	N/A
9/30/2020	161	13	10	19	N/A
6/30/2020	160	13	4	12	N/A
3/31/2020	167	17	11	17	N/A
12/31/2019	174	21	18	21	N/A
9/30/2019	167	22	19	21	N/A
6/30/2019	161	24	19	22	N/A
3/31/2019	158	23	17	19	N/A
12/31/2018	154	22	15	16	N/A
9/30/2018	151	18	13	14	N/A
6/30/2018	149	14	10	11	N/A
3/31/2018	143	12	11	14	N/A
12/31/2017	137	11	14	17	N/A
9/30/2017	131	11	N/A	18	N/A
6/30/2017	126	10	N/A	19	N/A
3/31/2017	123	11	N/A	20	N/A
12/31/2016	118	8	N/A	16	N/A
12/31/2015	110	8	N/A	16	N/A
12/31/2014	101	6	N/A	23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.5% al año) de 1696 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que los beneficios (11.5% al año) de 1696 crezcan menos que el mercado Hong Kong (11.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 1696 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (8.4% al año) de 1696 crezcan más rápidamente que los del mercado Hong Kong (7.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.4% al año) de 1696 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 1696 sea baja dentro de 3 años (8.3%).

Sisram Medical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

Sisram Medical Ltd Provides Earnings Guidance for the Year Ending December 31, 2021

Sisram Medical Ltd Provides Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Sisram Medical Ltd Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2023

Sisram Medical Ltd to Report Fiscal Year 2023 Results on Mar 20, 2024

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Investor sentiment deteriorates as stock falls 20%

Now 21% overvalued

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Sisram Medical Ltd Announces the Registration Application of Profhilo

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 19%

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

First half 2023 earnings released: EPS: US$0.04 (vs US$0.044 in 1H 2022)

Upcoming dividend of HK$0.17 per share at 2.3% yield

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Sisram Medical Ltd Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable 07 September 2023

Sisram Medical Announces the Launch of Alma Veil for the U.S. Market

Sisram Medical Ltd. Receives the Clearance from the U.S. Food and Drug Administration

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 16%

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

Sisram Medical Ltd, Annual General Meeting, Jun 28, 2023

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.086 (vs US$0.069 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Sisram Medical Ltd Announces Resignation of Mr. Guojun Bu from the Position of Executive Director of the Company with Effect from January 1, 2023

Investor sentiment improved over the past week

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Less than half of directors are independent

Investor sentiment improved over the past week

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Investor sentiment deteriorated over the past week

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

First half 2022 earnings released: EPS: US$0.044 (vs US$0.037 in 1H 2021)

Sisram Medical Ltd SHARE to Be Deleted from OTC Equity

Upcoming dividend of HK$0.16 per share

Sisram Medical Ltd to Report Q2, 2022 Results on Aug 19, 2022

Sisram Medical Ltd Declares Final Dividend for the Year Ended December 31, 2021, Payable on or Around 2 September 2022

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Investor sentiment deteriorated over the past week

Sisram Medical Ltd Announces Phase IIb Clinical Result on Submental Fat Reduction of JS-001

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sisram Medical Ltd Announces Resignation of Yao WANG as Non-Executive Director

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?

Full year 2021 earnings released: EPS: US$0.069 (vs US$0.03 in FY 2020)

Less than half of directors are independent

If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late

Investor sentiment improved over the past week

Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Sisram Medical Ltd to Report Fiscal Year 2021 Results on Mar 16, 2022

Investor sentiment deteriorated over the past week

Sisram Medical Ltd Provides Earnings Guidance for the Year Ending December 31, 2021

Executive Chairman recently bought HK$267k worth of stock